Calidi Biotherapeutics In... (CLDI)
AMEX: CLDI
· Real-Time Price · USD
5.28
0.24 (4.76%)
At close: Aug 15, 2025, 3:59 PM
5.24
-0.76%
After-hours: Aug 15, 2025, 07:55 PM EDT
Calidi Biotherapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
Revenue | n/a | n/a | 1.5M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 407K | 394K | n/a | 390K | 378K | 374K | 364K | 100K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -407K | -394K | 752K | -390K | -378K | -374K | -364K | -100K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -5.66M | -5.06M | -4.03M | -5.23M | -5.77M | -6.75M | -9.82M | -7.22M | -1.5M | -2.03M | -2.71M | -1.06M | -361.62K | -528.86K | -603.52K | -1.09M | -10K |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 493.56K | n/a | n/a | n/a | 160K | 16.5K | n/a | n/a | n/a |
Pretax Income | -5.76M | -5.06M | -4.14M | -5.07M | -5.76M | -7.22M | -8.23M | -2.01M | -4.19M | -2.16M | -2.44M | 697.26K | 4.16M | 1.46M | 4.29M | -823.29K | -10K |
Net Income | -5.71M | -4.99M | -4.1M | -5.05M | -5.77M | -7.22M | -8.23M | -2.02M | -12.5M | -6.46M | -7.76M | -5.36M | 4.16M | 1.46M | -3.49M | -823.29K | -10K |
Selling & General & Admin | 3.07M | 2.64M | 2.21M | 3.07M | 3.6M | 3.63M | 5.5M | 3.87M | 1.5M | 2.03M | 2.71M | 1.06M | 361.62K | 528.86K | 603.52K | 1.09M | 10K |
Research & Development | 2.59M | 2.42M | 1.81M | 2.15M | 2.17M | 2.74M | 3.96M | 3.25M | 3.18M | 2.62M | 2.26M | 1.95M | n/a | n/a | n/a | n/a | n/a |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -16K | -5K | -13K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 5.66M | 5.06M | 4.03M | 5.23M | 5.77M | 6.38M | 9.46M | 7.12M | 1.5M | 2.03M | 2.71M | 1.06M | 361.62K | 528.86K | 603.52K | 1.09M | 10K |
Interest Expense | 52K | 72K | 175K | 232K | 273K | 253K | 222K | 324K | 306K | 217K | 98K | 29K | n/a | n/a | 62K | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | -374K | -364K | -100K | -1.86M | -762.79K | 289.76K | -2.08M | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 5.66M | 5.06M | 4.03M | 5.23M | 5.77M | 6.75M | 9.82M | 7.22M | 1.5M | 2.03M | 2.71M | 1.06M | 361.62K | 528.86K | 603.52K | 1.09M | 10K |
Income Tax Expense | 4K | 3K | 3K | 1K | 8K | 4K | -3K | 11K | 77.95K | 65.47K | 143.3K | 203.69K | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 2.88M | 2.25M | 664.41K | 649.39K | 442.22K | 295.08K | 294.83K | 118.77K | 81.99K | 81.99K | 81.99K | 219.9K | 238.63K | 238.63K | 238.63K | 238.63K | 238.63K |
Shares Outstanding (Diluted) | 2.88M | 2.25M | 664.41K | 649.39K | 442.22K | 295.08K | 294.83K | 118.77K | 81.99K | 81.99K | 81.99K | 219.9K | 238.63K | 238.63K | 238.63K | 238.63K | 238.63K |
EPS (Basic) | -1.99 | -2.21 | -2.37 | -7.8 | -16.8 | -24.42 | -27.8 | -16.97 | -51.84 | -27 | -31.44 | 2.28 | 17.40 | 6.12 | 17.88 | -3.48 | -0.04 |
EPS (Diluted) | -1.99 | -2.21 | -2.37 | -7.8 | -16.8 | -24.42 | -27.8 | -16.97 | -51.84 | -27 | -31.44 | 2.28 | 17.40 | 6.12 | 17.88 | -3.48 | -0.04 |
EBITDA | -5.66M | -4.59M | -3.58M | -4.45M | -5.11M | -6.59M | -7.65M | -1.34M | -1.5M | -5.32M | -8.79M | -5.33M | -361.62K | -528.86K | -2.79M | -1.09M | -10K |
EBIT | -5.71M | -4.99M | -3.97M | -4.84M | -5.49M | -6.97M | -8.01M | -1.69M | -4.17M | -6.24M | -7.66M | -5.33M | 4.16M | 1.46M | -3.42M | -823.29K | -10K |
Depreciation & Amortization | 407K | 394K | 393K | 390K | 378K | 374K | 364K | 345K | 364K | 183K | 91K | 62K | n/a | n/a | n/a | n/a | n/a |